PepsiCo Stock Drops as GLP-1 Drugs Impact Sales

PepsiCo, Inc. is revising its brand portfolio to address a decline in stock price and shifting consumer eating habits. The company reported second-quarter 2026 organic sales growth of 2.4%, a figure that trailed the 6% growth achieved by its primary competitor, The Coca-Cola Company.

Wall Street analysts attribute the slowdown to increased health consciousness among consumers and the widespread adoption of GLP-1 weight-loss drugs, both of which have reduced demand for traditional snack and beverage products. In response to these headwinds, the company is updating its product offerings to better align with current health trends.

Despite the sales slump, the company continues to offer a dividend yield of approximately 4.3%, which remains significantly higher than the consumer staples average of 2.1% and the S&P 500 average of 1%. This performance maintains a 54-year history of consecutive dividend increases.